Sperimentazioni cliniche attive


A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis.

A phase II open-label randomized study of dietary supplement with epigallocatechin gallate (EGCG) to improve cardiac dysfunction in patients with AL amyloidosis who do not require chemotherapy (EpiCardiAL).

An open-label, phase II study of pomalidomide and dexamethasone (PDex) for previously treated patients with AL amyloidosis.

An Open Label Phase II Trial of Free Light Chain Removal by Extended High Cut-Off Hemodialysis in Patients with Advanced Cardiac AL Amyloidosis and End-Stage Renal Disease (DiACAL).

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed/Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment.


Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis.

The effect of Diflunisal on familial amyloidosis (IND 68092): A randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal. A randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal on neurologic disease progression in 200 familial amyloid subjects.

A single center, twelve-month, open-label, prospective study followed by a six-month withdrawal period to evaluate the efficacy, tolerability, safety and pharmacokinetics (PK) of dosycycline in combination with tauroursodeosycholic acid (TUDCA) in adults with transthyretin amyloidosis (ATTR).


An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).


International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Funcion Decline in Patients With AA Amyloidosis.